Original Research

Published in:
Volume 4 / Year 2015 / Issue 1

Payer and physician evidence and discount requirements for biosimilars in three Latin American countries

Author(s): , , , ,
Page: 11-6

Study objectives: In Latin America, many governments have attempted to address biosimilar safety and efficacy concerns by developing abbreviated regulatory pathways to increase access while controlling quality. This study explores… Read More »

What pricing and reimbursement policies to use for off-patent biologicals? – Results from the EBE 2014 biological medicines policy survey

Page: 17-24

Objective: One of the questions that the advent of biosimilars raises is whether the different nature of biological medicines would also imply the need for a different policy approach by… Read More »

Go Back Print